Trial Profile
Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 5 - 800 mg). A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Study, Including Re-dosing at 100 mg and 500 mg (Solution) and at 200 mg (Four 50 mg Tablets)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 44370 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Aug 2014 New trial record